Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 44171 for:    intensity

High Intensity Interval Training: Physiological Adaptation and Intervention Fidelity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03700671
Recruitment Status : Completed
First Posted : October 9, 2018
Last Update Posted : October 9, 2018
Sponsor:
Collaborator:
University of Hull
Information provided by (Responsible Party):
Stefan Birkett, University of Central Lancashire

Brief Summary:
The relationship between training frequency and adaptation is unclear following low-volume high intensity interval training (LV-HIIT), and intervention fidelity is poorly reported. We investigated the effects of a LV-HIIT protocol and moderate intensity continuous training (MICT) on cardiorespiratory fitness (CRF), and fidelity to the prescribed exercise intensity.

Condition or disease Intervention/treatment Phase
High Intensity Interval Training Other: High intensity interval training Other: Moderate intensity continuous training Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants were randomised to either high or moderate intensity exercise
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Low-Volume High Intensity Interval Training: Physiological Adaptation and Intervention Fidelity in Healthy Adults
Actual Study Start Date : May 11, 2016
Actual Primary Completion Date : May 11, 2017
Actual Study Completion Date : December 13, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: High intensity interval training
LV-HIIT was set at > 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
Other: High intensity interval training
Participants performed LV-HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration

Active Comparator: Moderate intensity continuous training
The MICT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of MICT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
Other: Moderate intensity continuous training
The MICT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of MICT with duration gradually increased to the desired 40 minutes as tolerated




Primary Outcome Measures :
  1. Maximal Oxygen Consumption (ml.kg-1.min-1) [ Time Frame: 8 weeks ]
    Maximal oxygen uptake (VO2max), as determined during a cardiopulmonary exercise test (CPET) represents the upper limit of aerobic fitness in humans. A low VO2max is associated with a greater risk of premature all-cause and cardiovascular mortality, independent of traditional risk factors and physical activity status. Conversely, increasing VO2max through exercise training may improve cardiometabolic health, quality of life and increase life-expectancy


Secondary Outcome Measures :
  1. Individual Responses to the interventions [ Time Frame: 8 weeks ]
    How many participants increased in fitness

  2. Fidelity [ Time Frame: 8 weeks ]
    Did participants comply with the exercise protocols



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants reported no medical history of cardiometabolic or limiting respiratory disease, were non-smokers, had a body mass index <30 kg.m-2, classified as recreationally active

Exclusion Criteria:

  • Cardiometabolic disease, high activity levels, Unable to tolerate the exercise intervention

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03700671


Locations
Layout table for location information
United Kingdom
Univeristy of Hull
Hull, Kingston Upon Hull, United Kingdom, HU67RX
Sponsors and Collaborators
University of Central Lancashire
University of Hull

Publications of Results:

Other Publications:
Richardson JTE. Eta squared and partial eta squared as measures of effect size in educational research. Educational Research Review. 2011;6(2):135-47. doi:https://doi.org/10.1016/j.edurev.2010.12.001.

Layout table for additonal information
Responsible Party: Stefan Birkett, Lecturer in Exercise Science, University of Central Lancashire
ClinicalTrials.gov Identifier: NCT03700671     History of Changes
Other Study ID Numbers: UCentralLancashire
First Posted: October 9, 2018    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No